August 2025
-
BriaCell Sets Proposed Effective Date for Share Consolidation
BriaCell Therapeutics (BCTX) announced a 1-for-10 reverse stock split, effective August 25, 2025, to maintain Nasdaq listing compliance. Shareholders receive one new share for every ten held; fractional shares of 0.5 or greater will be rounded up. The company’s convertible securities will be proportionally adjusted. Post-consolidation, BriaCell will continue trading under BCT (TSX) and BCTX (Nasdaq). Registered shareholders will receive transmittal letters with exchange instructions. The reverse split aims to increase the share price and maintain access to capital markets.
